Lv5
840 积分 2023-04-19 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
7小时前
已完结
自身免疫性视网膜病变的临床特征与研究进展
22天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
28天前
已完结
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis
28天前
已关闭
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis
29天前
已关闭
Risk of pituitary immune-related adverse events caused by immune checkpoint inhibitors:a systematic review and meta-analysis
1个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
3个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
4个月前
已完结
皖公网安备34019202002308
